生物制药公司Pharvaris N.V.（PHVS）今日盘中股价大幅下跌8.82%，引发投资者关注。这一显著跌幅与公司刚刚发布的2024财年财务报告密切相关。
根据Pharvaris N.V.公布的财报显示，公司2024财年净亏损达1.45亿美元，较上一财年亏损幅度扩大33.03%。值得注意的是，公司在本财年并未录得任何营业收入，每股基本亏损为2.69美元。这些数据反映出公司目前面临的财务压力，也解释了投资者对公司前景的担忧情绪。
Pharvaris N.V.是一家专注于开发用于预防和治疗遗传性血管性水肿（HAE）的新型口服药物的后期生物制药公司。尽管公司在研发方面取得了一定进展，包括正在进行的关键3期临床试验，但持续的高额研发投入和缺乏收入来源显然对公司的财务状况造成了严重影响。市场对这家生物科技公司能否在短期内实现盈利持谨慎态度，这也反映在了今日的股价表现上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.